[1]姚嘉嘉 卢祖能.急性缺血性脑卒中患者rt-PA静脉溶栓治疗新进展[J].卒中与神经疾病杂志,2021,28(03):355-358.[doi:10.3969/j.issn.1007-0478.2021.03.022]
点击复制

急性缺血性脑卒中患者rt-PA静脉溶栓治疗新进展()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第28卷
期数:
2021年03期
页码:
355-358
栏目:
综述
出版日期:
2021-06-25

文章信息/Info

文章编号:
1007-0478(2021)03-0355-04
作者:
姚嘉嘉 卢祖能
作者单位:430060 武汉大学人民医院神经内科[姚嘉嘉 卢祖能(通信作者)]
分类号:
R743.3
DOI:
10.3969/j.issn.1007-0478.2021.03.022
文献标志码:
A

参考文献/References:

[1]Seminar HJ. Stroke[J]. Lancet, 2017, 389(10069): 641654.
[2]中华医学会神经病学分会.中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666681.
[3]Powers WJ, Rabinstein AA, Ackerson TA, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association[J]. Stroke, 2018, 49(3): E46E110.
[4]Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke[J]. Stroke, 2019, 50(12): e344e418.
[5]Phipps MS, Cronin CA. Management of acute ischemic stroke[J]. BMJ (online), 2020, 368: 16983.
[6]National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke[J]. N Engl J Med, 1995, 333(24): 15811587.
[7]Hacke W KM, Ecass I. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med, 2008, 359(13): 13171329.
[8]Group Collaborative IST3, Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST3]): a randomised controlled trial[J]. Lancet, 2012, 379(9834): 23522363.
[9]Lyden PD. Thrombolytic therapy for acute ischemic stroke[J]. Stroke, 2019, 50(9): 25972603.
[10]Ehrlich ME, Liang L, Xu H, et al. Intravenous TissueType plasminogen activator in acute ischemic stroke patients with history of stroke plus diabetes mellitus[J]. Stroke, 2019, 50(6): 14971503.
[11]Tsivgoulis G, Katsanos AH, Mavridis D, et al. Association of baseline hyperglycemia with outcomes of patients with and without diabetes with acute ischemic stroke treated with intravenous thrombolysis: a propensity ScoreMatched analysis from the SITSISTR registry[J]. Diabetes, 2019, 68(9): 18611869.
[12]Gumbinger C, Ringleb P, Ippen F, et al. Stroke working group of BadenWürttemberg[J]. Outcomes of patients with stroke treated with thrombolysis according to prestroke Rankin Scale scores.Neurology, 2019, 93(20): e1834e1843.
[13]Sarmiento R, Diestro J, Espiritu A, et al. Safety and efficacy of repeated thrombolysis with alteplase in early recurrent ischemic stroke: a systematic review[J]. J Stroke Cerebrovasc Dis, 2019, 28(10): 104290.
[14]Anderson CS, Huang Y, Lindley RI, et al. ENCHANTED investigators and coordinators[J]. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke(ENCHANTED):an international,randomised,openlabel,blindedendpoint,phase 3 trial.Lancet, 2019, 393(10174): 877888.
[15]Wang X, Song L, Yang J, et al. Interaction of blood pressure lowering and alteplase dose in acute ischemic stroke: results of the enhanced control of hypertension and thrombolysis stroke study[J]. Cerebrovasc Dis, 2019, 48(3/6): 207216.
[16]Tsivgoulis G, Katsanos AH, Mandava P, et al.Blood pressure excursions in acute ischemic stroke patients treated with intravenous thrombolysis[Z], 2020.
[17]Shahjouei S, Tsivgoulis G, Goyal N, et al. Safety of intravenous thrombolysis among patients taking direct oral anticoagulants: a systematic review and MetaAnalysis[J]. Stroke, 2020, 51(2): 533541.
[18]Touzé E, Gruel Y, GouinThibault I, et al. Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants[J]. European Journal of Neurology, 2018, 25(5): e52747.
[19]Schiele F, Van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization[J]. Blood, 2013, 121(18): 35543562.
[20]Intravenous thrombolysis in patients with acute ischemic stroke after a reversal of dabigatran anticoagulation with idarucizumab: a RealWorld clinical experience[J]. J Stroke Cerebrovasc Dis, 2018, 27(9): 24792483.
[21]Dodds JA, Xian Y, Sheng S, et al. Thrombolysis in young adults with stroke: Findings from Get With The GuidelinesStroke[J]. Neurology, 2019, 92(24): e2784e2792.
[22]Papavasileiou V, Goldstein LB. Thrombolysis in young adults with acute ischemic stroke: Quicker May be better[J]. Neurology, 2019, 92(24): 11291130.
[23]Thomalla G SC, Investigators WU. MRIguided thrombolysis for stroke with unknown time of onset[J]. N Engl J Med, 2018, 379(7): 611622.
[24]Seyhan M, Mackenrodt D, Gunreben I, et al. Should IV thrombolysis be given in patients with suspected ischemic stroke but unknown symptom onset and without DiffusionWeighted imaging lesion  results of a CaseControl study[J]. J Stroke Cerebrovasc Dis, 2020, 29(2): 104515.
[25]Ma H CB, Extend I. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke[J]. N Engl J Med, 2019, 380(19): 17951803.
[26]Furlanis G, Ajcevic M, Buoite SA, et al. Wake up stroke: thrombolysis reduces ischemic lesion volume and neurological deficit[J]. J Neurol, 2020, 267(3): 666673.
[27]Polymeris Aa CS, Trisp C. Intravenous thrombolysis for suspected ischemic stroke with seizure at onset[J]. Ann Neurol, 2019, 86(5): 770779.
[28]He L, Xu R, Wang J, et al. Capsular warning syndrome: clinical analysis and treatment[J]. BMC Neurol, 2019, 19(1): 285.
[29]Burgos AM, Saver JL. Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: MetaAnalysis of 5 Randomized Trials[J]. Stroke, 2019, 50(8): 21562162.
[30]Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NORTEST): a phase 3, randomised, openlabel, blinded endpoint trial[J]. Lancet Neurol, 2017, 16(10): 781788.
[31]Kvistad CE, Novotny V, Kurz MW, et al. Safety and outcomes of tenecteplase in moderate and severe ischemic stroke[J]. Stroke, 2019, 50(5): 12791281.
[32]乔雨林,向文强,王磊,等.急性缺血性脑卒中患者使用替奈普酶和阿替普酶的溶栓研究[J].脑与神经疾病杂志,2018,26(7):444450.
[33]Campbell B, Mitchell PJ, Churilov L, et al. EXTENDIA TNK investigators[J]. Tenecteplase versus alteplase before thrombectomy for ischemic stroke.N Engl J Med, 2018, 378(17): 15731582.
[34]Tseng YJ, Hu RF, Lee ST, et al. Risk factors associated with outcomes of recombinant tissue plasminogen activator therapy in patients with acute ischemic stroke[J]. Int J Environ Res Public Health, 2020, 17(2): 618.
[35]Braemswig TB, Villringer K, Turc G, et al. Predictors of new remote cerebral microbleeds after IV thrombolysis for ischemic stroke[J]. Neurology, 2019, 92(7): e630e638.
[36]Sun H, Liu Y, Gong P, et al. Intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign: A metaanalysis[J]. Acta Neurol Scand, 2020, 141(3): 193201.
[37]Huhtakangas JK, Saaresranta T, Bode MK, et al. Stroke volume predicts nocturnal hypoxemia in the acute ischemic stroke after intravenous thrombolysis[J]. J Stroke Cerebrovasc Dis, 2019, 28(9): 24812487.
[38]Wen L, Zhang S, Wan K, et al. Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous thrombolysis: A metaanalysis[J]. Medicine (Baltimore), 2020, 99(7): e18995.
[39]Wang X, Li J, Moullaali TJ, et al. Lowdose versus standarddose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study[J]. Int J Stroke, 2019, 14(7): 670677.

更新日期/Last Update: 2021-06-25